

## 2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest

**Name: Verstockt, Bram**

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'25 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'25 presentations, the 2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
  - I have no potential conflict of interest to disclose
  - I have potential conflict of interest to disclose
- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
  - Grant
  - Personal Fees
  - Non-financial support
  - Other

### **Disclosures statement based on answers received:**

**Grant: |Research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sosei Heptares and Takeda. | Personal Fees: |-Speaker's fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Eli Lilly, Falk, Ferring, Galapagos, Johnson and Johnson, MSD, Pfizer, R-Biopharm, Sandoz, Takeda, Tillots Pharma, Truvion and Viatris. |-Consultancy fees from Abbvie, Alfasigma, Alimentiv, Applied Strategic, Astrazeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Eli Lilly, Galapagos, Guidepont, Landos, Merck, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Pfizer, Progenity, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma and Viatris. | Non-financial Support: |Stock options Vagustim**